How to Buy Capricor Therapeutics Stock
Capricor Therapeutics Inc
Capricor Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.
Capricor Therapeutics stock last closed at $24.04, down 3.03% from the previous day, and has increased 78.47% in one year. It has overperformed other stocks in the Biotechnology industry by 1.14 percentage points. Capricor Therapeutics stock is currently +459.07% from its 52-week low of $4.30, and -40.45% from its 52-week high of $40.37.
There are currently 45.72M shares of CAPR outstanding. The market cap of CAPR is $1.10B. In the past 24 hours, 1.6M CAPR shares were traded.
How to Buy Capricor Therapeutics Stock
Not sure how to invest in Capricor Therapeutics stock? Here's how.
- Decide where to buy Capricor Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you choose where to buy Capricor Therapeutics stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your brokerage account: Select your method of payment and add your information.
- Evaluate Capricor Therapeutics stock: The Capricor Therapeutics ticker symbol is CAPR. Is Capricor Therapeutics stock a good investment? Should you buy shares of CAPR? How do CAPR's underlying business fundamentals look? Do top analysts think Capricor Therapeutics is a good buy? Why has CAPR's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if CAPR is a good stock to buy).
- Make your CAPR trade: Decide if you will purchase CAPR shares at the current market price or use a limit order to purchase CAPR shares at a given price.
- Get notifications regarding your investment in CAPR: Create a watchlist to get live updates on your new investment in Capricor Therapeutics shares.
Step 1: Decide where to buy Capricor Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy CAPR shares.
Our preferred brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the right brokerage, it's time to fill out some personal information so you are able to buy CAPR today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to start a new brokerage account.
- Submit your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have opened your account on one of the most highly reviewed stock apps, you need to deposit funds:
Check out this video walkthrough to see the process of transferring funds into your investment account.
Step 4: Evaluate Capricor Therapeutics stock
Once you have selected the best place to buy Capricor Therapeutics stock, it's absolutely critical to evaluate their stock prior to investing, so you truly understand the risk and upside.
Capricor Therapeutics Metrics
CAPR Due Diligence Checks
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CAPR's stock page.
Is CAPR stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge CAPR's true value.
Using relative valuations ratios:
- CAPR could be overvalued based on its P/B ratio of 13.1x, relative to Biotechnology industry P/B ratio of 5.4x
You can do more valuation analysis on CAPR's stock here.
A quick look at CAPR Financials
Pros:
- CAPR has cash burn of 68375008. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the CAPR balance sheet.
- There are more short-term assets than short-term liabilities on the CAPR balance sheet.
- CAPR has $98.57M in cash and short term investments. This is enough to cover its annual cash burn of $68.38M.
Cons:
- Total CAPR debt is higher than 5 years ago, relative to shareholder equity.
- CAPR profit margin has gone down from -146.9% to -736.6% in the past year.
- CAPR has a relatively high debt to equity ratio of 0.51.
Is it a good time to buy CAPR stock, according to Wall Street analysts?
Out of 6 Equities analysts who monitor CAPR, the consensus analyst rating on Capricor Therapeutics is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Latest CAPR Analyst Recommendations
Boobalan Pachaiyappan, a top 12% analyst from Roth Capital maintains CAPR with a strong buy rating and raises their CAPR price target from $12.00 to $13.00, on Nov 12, 2025.
Roth Capital's Boobalan Pachaiyappan raised their price target on Capricor Therapeutics (NASDAQ: CAPR) by 8.3% from $12 to $13 on 2025/11/12. The analyst maintained their Strong Buy rating on the stock.
Capricor Therapeutics reported its Q3 2025 earnings.
Pachaiyappan said their price target hike was catalyzed by an expectation that, at the very least, the Phase 3 HOPE-3 results coming in Q4 will evidence cardiac improvements, positioning the company to pressure the FDA to exercise regulatory flexibility to approve Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy.
The analyst added that their model assumes Deramiocel's approval in this sub-disease area.
Earnings Report
For Q3 2025, Capricor Therapeutics reported:
- EPS of $(0.54), which met the consensus estimate but missed Q3 2024's $(0.38).
- Revenue of $0.00, which missed the $0.6M consensus estimate and Q3 2024's $2.3M.
Management did not provide financial guidance in its press release.
CEO Linda Marbán, Ph.D., commented: “We are entering one of the most pivotal periods in Capricor’s history as we approach the topline readout from our HOPE-3 Phase 3 trial of Deramiocel for the treatment of Duchenne muscular dystrophy.
“Deramiocel was developed to address the cardiomyopathy that ultimately claims the lives of nearly all patients with Duchenne, and our mission has never been clearer: to bring forward the first therapy specifically designed to target this life-limiting aspect of the disease.
"Over the past decade, we have generated compelling and statistically significant data showing durable improvements in both cardiac and skeletal muscle function.
"With our commercial-ready manufacturing facility in place and our Pre-License Inspection completed, we believe we are well-positioned for potential approval and launch.
"We remain confident in the strength, consistency, and reproducibility of our science and are fully focused on advancing Deramiocel toward approval and commercialization, with the broader goal of delivering meaningful and lasting value to patients, families, and shareholders.”
You can dive deeper into what analysts are projecting on the Capricor Therapeutics stock forecast page.
CAPR Technicals
CAPR Earnings
Last year, CAPR revenue was $11.13M. During the last five year, CAPR's revenue has gone up by 87.95% per year. This was faster than the Biotechnology industry average of 43.28%.
Learn more about CAPR's earnings and revenue performance here.
Who is buying/selling CAPR?
In the past 12 months, executives and large shareholders at CAPR have bought more shares than they have sold.
George W. Dunbar Jr., Director of CAPR, was the latest CAPR insider to buy. They bought $4,170.00 worth of CAPR shares on Dec 19, 2025.
Research more about who owns CAPR stock here.
Does CAPR stock generate passive income?
No, Capricor Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Make your CAPR trade
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Click the Open button and your broker will place the order.
If you need additional help buying stocks on eToro, watch the how to video below:
Step 6: Get notifications regarding your investment in CAPR
Now that you own some shares in CAPR, you'll want to keep up with your investment.
Start a watchlist to keep track of your CAPR stock.
CAPR Feed
How to Buy Stock in Capricor Therapeutics
To summarize, here are the 6 steps to buy stock in Capricor Therapeutics:
- Decide where to buy Capricor Therapeutics stock
- Create your brokerage account
- Deposit money your brokerage account
- Evaluate Capricor Therapeutics stock
- Make your CAPR trade
- Get notifications regarding your investment in CAPR
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep tabs on your new investment in Capricor Therapeutics, get started below.
Other Content You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.